政府规制、买方势力与技术创新:中国制药产业的研究  

Government Regulation,Buyer Power and Technical Innovation:A Study of China’s Pharmaceutical Industry

作　　者：张庆霖[1] 郭嘉仪[2] 

机构地区：[1]广东商学院公共管理学院,广东广州510320 [2]广东商学院财政税务学院,广东广州510320

出　　处：《当代财经》2013年第6期98-109,共12页Contemporary Finance and Economics

基　　金：广东省自然科学基金项目"纵向市场下的政府规制与创新决策:基于制药产业的研究"(S2012040007203);广东高校优秀青年创新人才培养项目"制度结构;创新效率与产业升级:基于上市公司特质信息的研究"(2012WYM_0066)

摘　　要：虽然针对药品市场的政府规制旨在降低患者药费支出和确保用药安全,但其对我国制药产业技术创新的负面影响是显而易见的,产业创新产出扭曲,创制新药难得一觅,虚假"新药"泛滥市场。另一方面,正是结合不合理的医疗卫生规制安排,医疗机构得以利用其在药品市场中的双边垄断势力扭曲药品需求结构,并传递到上游产业,从而引致制药产业的创新投入降低并扭曲创新结构。基于政府规制和买方势力的视角,利用面板数据的实证分析结果也印证了政府规制和买方势力对制药产业技术创新投入和产出有着显著的负面效应。从政策意义上说,放松政府规制或引入政府规制影响评价,同时限制医疗机构利用垄断地位滥用市场势力对于引导我国制药产业技术创新回到良性轨道是可参考的政策选择。Although the government regulation over the pharmaceutical markets aims at reducing patients＇ medical expenses and protecting medical safety, its negative influence on the technical inno-vations of China＇s pharmaceutical industry is obvious. The pharmaceutical industry has some innova-tions but its output is distorted, newly invented medicine is difficult to find, while mendacious new drugs are flooding in the markets. On the other hand, because of the unreasonable regulation system of medical and health departments, the medical institutions can take advantages of its bilateral monopoly power in drug markets to distort the drug demand structure and transfer it to the upstream industry. Thus, the innovation input is reduced and its structure is distorted in the pharmaceutical in-dustry. From the perspective of government regulation and buyer power, this empirical analysis of the panel data also confirms that the government regulation and buyer power have significant negative ef-fect on the input and output of technical innovation in the pharmaceutical industry. As for policy sug-gestions, in order to lead the technical innovation of China＇s pharmaceutical industry to the right track, the following policy selections earl be taken for reference, such as relaxing government regula-tion or introducing assessment method for government regulatory impact, while at the same time lim-iting the monopoly power of the medical institutions.

关 键 词：政府规制 买方势力 技术创新 制药产业 

分 类 号：F260[经济管理—国民经济]